Pomerantz Law Firm Initiates Class Action Against 3D Systems Corporation Over Securities Violations
On July 12, 2025, Pomerantz LLP announced the initiation of a class action lawsuit against 3D Systems Corporation (NYSE: DDD) and certain of its executives in the United States District Court for the District of Delaware. The case, identified as docket 25-cv-00734, encompasses all individuals and entities who acquired 3D Systems securities between August 13, 2024, and May 12, 2025. This lawsuit aims to recover losses resulting from alleged infractions of federal securities laws by the defendants. Investors who fall within this timeframe have until August 12, 2025, to move for lead plaintiff status in the class action. Interested parties can find additional information and a copy of the complaint through Pomerantz's website.
3D Systems Corporation operates in the field of 3D printing and digital manufacturing solutions on a global scale, including regions like North America, South America, Europe, the Middle East, Africa, Asia, and Oceania. It generates revenue through two primary segments: Healthcare Solutions and Industrial Solutions. Notably, the Healthcare segment encompasses various products and services, including those related to dental, medical devices, personalized health services, and its Regenerative Medicine Program, which focuses on using additive manufacturing for human organ transplants.
In recent developments, 3D Systems has partnered with United Therapeutics Corporation, aiming to leverage 3D printing technology to create transplantable lungs for individuals suffering from severe lung diseases. This collaboration, referred to as the United Partnership, includes stipulated milestone criteria, which were revised in late 2024 due to adjustments in testing methodologies. Revenue recognition tied to this partnership is contingent upon achieving these milestones, posing unique challenges as these criteria evolve.
Despite facing a backdrop of reduced customer spending that has permeated the 3D printing industry, 3D Systems has conveyed optimism about its future, emphasizing recovery and a solid customer pipeline. The company recently projected annual revenue for 2025 to range between $420 million and $435 million, indicating modest growth. Additionally, it reported aiming for a non-GAAP gross profit margin within the range of 37% to 39% alongside operating expenses of $200 million to $220 million.
However, the lawsuit alleges that throughout the class period, the defendants misled investors by making materially false claims regarding 3D Systems’ business operations and adherence to regulatory standards. Specifically, it is claimed that the executives downplayed the detrimental effects of declining customer spending on the company's performance while misleadingly asserting its resilience during tough market conditions. The amended milestone criteria from the United Partnership were also cited as contributing to adverse effects on revenue from the Regenerative Medicine Program.
Following underwhelming fourth-quarter financial results for 2024, where 3D Systems reported non-GAAP earnings per share at -$0.19 and revenues of $111 million—falling short of expectations—the stock price took a significant hit. By March 27, 2025, 3D Systems’ shares had fallen to $2.15, reflecting a 20.96% drop.
On May 12, 2025, the company disclosed its first-quarter performance for 2025, posting a net loss of $37 million and a substantial year-over-year decline in revenues. This downturn prompted 3D Systems to withdraw its previously established guidance for the remainder of the year, citing ongoing challenges in customer spending and macroeconomic fluctuations.
In response, market analysts have expressed skepticism regarding 3D Systems' ability to achieve profitability, even post-significant stock value reductions. With a trend of continuous loss and declining sales figures, investor confidence remains shaky.
Pomerantz LLP, with its reputation as a leading law firm specializing in corporate, securities, and antitrust litigations, has a long-established history in recovering damages for parties affected by securities fraud. The firm actively advocates for investors' rights, continuing the legacy of its founder, Abraham L. Pomerantz, who was fundamental in creating the securities class actions landscape. More details on the complaint and the class action process can be accessed via the firm’s official website.